{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:52:00Z","timestamp":1698785520351},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11920-005-0034-3","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:21:11Z","timestamp":1180732871000},"page":"344-351","source":"Crossref","is-referenced-by-count":11,"title":["Expanding treatment of tobacco dependence"],"prefix":"10.1007","volume":"7","author":[{"given":"Debra S.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Anthenelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"34_CR1","first-page":"1","volume-title":"The World Health Report 2002: Reducing risks, promoting healthy life","author":"World Health Organization","year":"2002","unstructured":"World Health Organization: The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002:1\u201394."},{"key":"34_CR2","volume-title":"Substance Abuse: A Comprehensive Textbook","author":"ME Jarvik","year":"1992","unstructured":"Jarvik ME, Schneider NG: Nicotine. In Substance Abuse: A Comprehensive Textbook, Second Edition. Edited by Lowinson JH, Ruiz P, Millman RB. Baltimore: Lippincott, Williams & Wilkins; 1992.","edition":"Second Edition"},{"key":"34_CR3","volume-title":"Clinical Practice Guideline. Treating Tobacco Use and Dependence","author":"MC Fiore","year":"2000","unstructured":"Fiore MC, Bailey WC, Cohen SJ, et al.: Clinical Practice Guideline. Treating Tobacco Use and Dependence. Rockville, MD: US Department of Health and Human Services; 2000. Written by a panel of leading experts, this clinical practice guideline used meta-analytic strategies to summarize the state of science as of 1999, and make treatment recommendations based on these analyses."},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1055-9965.2012.13.12","volume":"13","author":"SS Gorin","year":"2004","unstructured":"Gorin SS, Heck JE: Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev 2004, 13:2012\u20132022.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/09595230410001645510","volume":"23","author":"AM Roche","year":"2004","unstructured":"Roche AM, Freeman T: Brief interventions: good in theory but weak in practice. Drug Alcohol Rev 2004, 23:11\u201318. This is a provocative review that explores reasons why brief interventions for tobacco dependence have failed to achieve optimum resultsin front-line clinical practice.","journal-title":"Drug Alcohol Rev"},{"key":"34_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/0959523031000154481","volume":"22","author":"RJ Tait","year":"2003","unstructured":"Tait RJ, Hulse GK: A systematic review of the effectiveness of brief interventions with substance using adolescents by type of drug. Drug Alcohol Rev 2003, 22:337\u2013346.","journal-title":"Drug Alcohol Rev"},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14622200412331324965","volume":"6","author":"DJ Balfour","year":"2004","unstructured":"Balfour DJ: The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine Tob Res 2004, 6:899\u2013912.","journal-title":"Nicotine Tob Res"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1037\/0022-006X.72.2.192","volume":"72","author":"S Shiffman","year":"2004","unstructured":"Shiffman S, Waters AJ: Negative affect and smoking lapses: a prospective analysis. J Consult Clin Psychol 2004, 72:192\u2013201.","journal-title":"J Consult Clin Psychol"},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0006-3223(00)01011-8","volume":"49","author":"JA Dani","year":"2001","unstructured":"Dani JA: Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001, 49:166\u2013174.","journal-title":"Biol Psychiatry"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/382255a0","volume":"382","author":"FE Pontieri","year":"1996","unstructured":"Pontieri FE, Tanda G, Orzi F, et al.: Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255\u2013257.","journal-title":"Nature"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1196\/annals.1300.011","volume":"1003","author":"ZM Fagen","year":"2003","unstructured":"Fagen ZM, Mansvelder HD, Keath JR, et al.: Short- and longterm modulation of synaptic inputs to brain reward areas by nicotine. Ann N Y Acad Sci 2003, 1003:185\u2013195.","journal-title":"Ann N Y Acad Sci"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuron.2004.09.016","volume":"44","author":"AE Kelley","year":"2004","unstructured":"Kelley AE: Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004, 44:161\u2013179.","journal-title":"Neuron"},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tips.2003.11.003","volume":"25","author":"TP George","year":"2004","unstructured":"George TP, O\u2019Malley SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004, 25:42\u201348.","journal-title":"Trends Pharmacol Sci"},{"key":"34_CR14","first-page":"407","volume":"175","author":"KE Hutchison","year":"2004","unstructured":"Hutchison KE, Rutter MC, Niaura R, et al.: Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology (Berl) 2004, 175:407\u2013413.","journal-title":"Psychopharmacology (Berl)"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00008877-200503000-00008","volume":"16","author":"SV Mahler","year":"2005","unstructured":"Mahler SV, de Wit H: Effects of haloperidol on reactions to smoking cues in humans. Behav Pharmacol 2005, 16:123\u2013126.","journal-title":"Behav Pharmacol"},{"key":"34_CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s002130100894","volume":"159","author":"LH Brauer","year":"2001","unstructured":"Brauer LH, Cramblett MJ, Paxton DA, et al.: Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl) 2001, 159:31\u201337.","journal-title":"Psychopharmacology (Berl)"},{"key":"34_CR17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14622200210153830","volume":"4","author":"NH Caskey","year":"2002","unstructured":"Caskey NH, Jarvik ME, Wirshing WC, et al.: Modulating tobacco smoking rates by dopaminergic stimulation and blockade. Nicotine Tob Res 2002, 4:259\u2013266.","journal-title":"Nicotine Tob Res"},{"key":"34_CR18","doi-asserted-by":"crossref","unstructured":"Hughes J, Stead L, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; CD000031.","DOI":"10.1002\/14651858.CD000031.pub2"},{"key":"34_CR19","doi-asserted-by":"crossref","unstructured":"Gourlay SG, Stead LF, Benowitz NL: Clonidine for smoking cessation. Cochrane Database Syst Rev 2004; CD000058.","DOI":"10.1002\/14651858.CD000058.pub2"},{"key":"34_CR20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1017\/S1461145701002188","volume":"4","author":"I Berlin","year":"2001","unstructured":"Berlin I, Anthenelli RM: Monoamine oxidases and tobacco smoking. Intl J Neuropsychopharmacol 2001, 4:33\u201342. This is an historical overview of the pharmacology and clinical relevance of the inibitory effects of tobacco smoke on MAO.","journal-title":"Intl J Neuropsychopharmacol"},{"key":"34_CR21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0009-9236(95)90058-6","volume":"58","author":"I Berlin","year":"1995","unstructured":"Berlin I, Said S, Spreux-Varoquaux O, et al.: A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995, 58:444\u2013452.","journal-title":"Clin Pharmacol Ther"},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"11600","DOI":"10.1073\/pnas.1833106100","volume":"100","author":"JS Fowler","year":"2003","unstructured":"Fowler JS, Logan J, Wang GJ, et al.: Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci U S A 2003, 100:11600\u201311605.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"34_CR23","doi-asserted-by":"crossref","unstructured":"Anthenelli RM: Recent advances in the treatment of tobacco dependence. Clin Neurosci Res 2005, In press.","DOI":"10.1016\/j.cnr.2005.08.014"},{"key":"34_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14622200050011277","volume":"2","author":"SS Watkins","year":"2000","unstructured":"Watkins SS, Koob GF, Markou A: Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000, 2:19\u201337.","journal-title":"Nicotine Tob Res"},{"key":"34_CR25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14622200110087277","volume":"3","author":"JE Rose","year":"2001","unstructured":"Rose JE, Behm FM, Ramsey C, et al.: Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res 2001, 3:383\u2013390.","journal-title":"Nicotine Tob Res"},{"key":"34_CR26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1530-0277.1998.tb04298.x","volume":"22","author":"RM Anthenelli","year":"1998","unstructured":"Anthenelli RM, Tipp J, Li TK, et al.: Platelet monoamine oxidase activity in subgroups of alcoholics and controls: results from the Collaborative Study on the Genetics of Alcoholism. Alcohol Clin Exp Res 1998, 22:598\u2013604.","journal-title":"Alcohol Clin Exp Res"},{"key":"34_CR27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-002-1152-9","volume":"163","author":"EJ Houtsmuller","year":"2002","unstructured":"Houtsmuller EJ, Thornton JA, Stitzer ML: Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 2002, 163:213\u2013220.","journal-title":"Psychopharmacology (Berl)"},{"key":"34_CR28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0006-3223(02)01454-3","volume":"53","author":"TP George","year":"2003","unstructured":"George TP, Vessicchio JC, Termine A, et al.: A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003, 53:136\u2013143.","journal-title":"Biol Psychiatry"},{"key":"34_CR29","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1360-0443.2003.00524.x","volume":"98","author":"R Biberman","year":"2003","unstructured":"Biberman R, Neumann R, Katzir I, et al.: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003, 98:1403\u20131407.","journal-title":"Addiction"},{"key":"34_CR30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-199733020-00002","volume":"33","author":"I Mahmood","year":"1997","unstructured":"Mahmood I: Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997, 33:91\u2013102.","journal-title":"Clin Pharmacokinet"},{"key":"34_CR31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<165::AID-BDD14>3.0.CO;2-S","volume":"18","author":"JS Barrett","year":"1997","unstructured":"Barrett JS, DiSanto AR, Thomford PJ, et al.: Toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm Drug Dispos 1997, 18:165\u2013184.","journal-title":"Biopharm Drug Dispos"},{"key":"34_CR32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1023\/A:1016035730754","volume":"13","author":"JS Barrett","year":"1996","unstructured":"Barrett JS, Szego P, Rohatagi S, et al.: Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res 1996, 13:1535\u20131540.","journal-title":"Pharm Res"},{"key":"34_CR33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2003.08.099","volume":"480","author":"HD Mansvelder","year":"2003","unstructured":"Mansvelder HD, De Rover M, McGehee DS, et al.: Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharmacol 2003, 480:117\u2013123.","journal-title":"Eur J Pharmacol"},{"key":"34_CR34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0091-3057(01)00652-9","volume":"70","author":"JA Dani","year":"2001","unstructured":"Dani JA, De Biasi M: Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001, 70:439\u2013446.","journal-title":"Pharmacol Biochem Behav"},{"key":"34_CR35","doi-asserted-by":"crossref","unstructured":"Silagy C, Lancaster T, Stead L, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; CD000146.","DOI":"10.1002\/14651858.CD000146.pub2"},{"key":"34_CR36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14728214.9.1.39","volume":"9","author":"J Foulds","year":"2004","unstructured":"Foulds J, Burke M, Steinberg M, et al.: Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004, 9:39\u201353.","journal-title":"Expert Opin Emerg Drugs"},{"key":"34_CR37","first-page":"321","volume":"295","author":"JE Slemmer","year":"2000","unstructured":"Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000, 295:321\u2013327.","journal-title":"J Pharmacol Exp Ther"},{"key":"34_CR38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14622200410001696501","volume":"6","author":"JE Rose","year":"2004","unstructured":"Rose JE, Behm FM: Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res 2004, 6:523\u2013532. This is a good example of a laboratory-based clinical trial evaluating the ways that pharmacologic and behavioral manipulations influence cues to smoke.","journal-title":"Nicotine Tob Res"},{"key":"34_CR39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0091-3057(00)00252-5","volume":"66","author":"LH Lundahl","year":"2000","unstructured":"Lundahl LH, Henningfield JE, Lukas SE: Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav 2000, 66:637\u2013643.","journal-title":"Pharmacol Biochem Behav"},{"key":"34_CR40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/BF02806011","volume":"127","author":"T Eissenberg","year":"1996","unstructured":"Eissenberg T, Griffiths RR, Stitzer ML: Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 1996, 127:328\u2013336.","journal-title":"Psychopharmacology"},{"key":"34_CR41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pbb.2003.08.011","volume":"76","author":"JE Rose","year":"2003","unstructured":"Rose JE, Behm FM, Westman EC, et al.: Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol Biochem Behav 2003, 76:307\u2013313.","journal-title":"Pharmacol Biochem Behav"},{"key":"34_CR42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF00518198","volume":"91","author":"CS Pomerleau","year":"1987","unstructured":"Pomerleau CS, Pomerleau OF, Majchrzak MJ: Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology (Berl) 1987, 91:391\u2013393.","journal-title":"Psychopharmacology (Berl)"},{"key":"34_CR43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/BF00178502","volume":"88","author":"R Nemeth-Coslett","year":"1986","unstructured":"Nemeth-Coslett R, Henningfield JE, O\u2019Keeffe MK, et al.: Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl) 1986, 88:420\u2013425.","journal-title":"Psychopharmacology (Berl)"},{"key":"34_CR44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF02247425","volume":"108","author":"PA Newhouse","year":"1992","unstructured":"Newhouse PA, Potter A, Corwin J, et al.: Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl) 1992, 108:480\u2013484.","journal-title":"Psychopharmacology (Berl)"},{"key":"34_CR45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/clpt.1994.105","volume":"56","author":"JE Rose","year":"1994","unstructured":"Rose JE, Behm FM, Westman EC, et al.: Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994, 56:86\u201399.","journal-title":"Clin Pharmacol Ther"},{"key":"34_CR46","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1099420","volume":"306","author":"AR Tapper","year":"2004","unstructured":"Tapper AR, McKinney SL, Nashmi R, et al.: Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004, 306:1029\u20131032.","journal-title":"Science"},{"key":"34_CR47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","volume":"391","author":"MR Picciotto","year":"1998","unstructured":"Picciotto MR, Zoli M, Rimondini R, et al.: Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173\u2013177.","journal-title":"Nature"},{"key":"34_CR48","unstructured":"Coe JW, Brooks PR, Vetelino MG, et al.: Varenicline (CP-526, 555): A novel, potent, and selective nicotinic receptor partial agonist for the treatment of smoking cessation: Rationale, discovery, and mode of action. Poster presented at the SRNT meeting in Prague, March 21, 2005."},{"key":"34_CR49","unstructured":"Oncken C, Watsky E, Reeves K, et al.: Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: Results from a Phase 2 study. Poster presented at the SRNT meeting in Prague, March 21, 2005."},{"key":"34_CR50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/jpet.103.049262","volume":"306","author":"C Cohen","year":"2003","unstructured":"Cohen C, Bergis OE, Galli F, et al.: SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003, 306:407\u2013420.","journal-title":"J Pharmacol Exp Ther"},{"key":"34_CR51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/sj.npp.1300524","volume":"30","author":"NE Paterson","year":"2005","unstructured":"Paterson NE, Froestl W, Markou A: Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 2005, 30:119\u2013128.","journal-title":"Neuropsychopharmacology"},{"key":"34_CR52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1098-2396(199901)31:1<76::AID-SYN10>3.0.CO;2-Y","volume":"31","author":"SL Dewey","year":"1999","unstructured":"Dewey SL, Brodie JD, Gerasimov M, et al.: A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31:76\u201386.","journal-title":"Synapse"},{"key":"34_CR53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/syn.20097","volume":"55","author":"JD Brodie","year":"2005","unstructured":"Brodie JD, Figueroa E, Laska EM, et al.: Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and\/or cocaine addiction. Synapse 2005, 55:122\u2013125.","journal-title":"Synapse"},{"key":"34_CR54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/syn.10000","volume":"42","author":"WK Schiffer","year":"2001","unstructured":"Schiffer WK, Gerasimov MR, Marsteller DA, et al.: Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 2001, 42:196\u2013198.","journal-title":"Synapse"},{"issue":"Suppl 1","key":"34_CR55","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1111\/j.1528-1157.2000.tb02171.x","volume":"41","author":"S Skradski","year":"2000","unstructured":"Skradski S, White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000, 41(Suppl 1):S45-S47.","journal-title":"Epilepsia"},{"key":"34_CR56","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.addbeh.2004.06.014","volume":"29","author":"BA Johnson","year":"2004","unstructured":"Johnson BA: Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 2004, 29:1465\u20131479.","journal-title":"Addict Behav"},{"key":"34_CR57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14622200310001656957","volume":"6","author":"JE Rose","year":"2004","unstructured":"Rose JE, Brauer LH, Behm FM, et al.: Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob Res 2004, 6:133\u2013144.","journal-title":"Nicotine Tob Res"},{"key":"34_CR58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0705726","volume":"142","author":"MA Diana","year":"2004","unstructured":"Diana MA, Marty A: Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 2004, 142:9\u201319.","journal-title":"Br J Pharmacol"},{"key":"34_CR59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-8993(02)03344-9","volume":"954","author":"S Gonzalez","year":"2002","unstructured":"Gonzalez S, Cascio MG, Fernandez-Ruiz J, et al.: Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002, 954:73\u201381.","journal-title":"Brain Res"},{"key":"34_CR60","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/j.1460-9568.2004.03714.x","volume":"20","author":"GN Balerio","year":"2004","unstructured":"Balerio GN, Aso E, Berrendero F, et al.: Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 2004, 20:2737\u20132748.","journal-title":"Eur J Neurosci"},{"key":"34_CR61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.npp.1300541","volume":"30","author":"C Cohen","year":"2005","unstructured":"Cohen C, Perrault G, Griebel G, et al.: Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB(1)) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005, 30:145\u2013155.","journal-title":"Neuropsychopharmacology"},{"key":"34_CR62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008877-200209000-00018","volume":"13","author":"C Cohen","year":"2002","unstructured":"Cohen C, Perrault G, Voltz C, et al.: SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002, 13:451\u2013463. This is the first study done in experimental animals that showed that inhibition of the endocannibinoid system dampens nicotine reinforcement.","journal-title":"Behav Pharmacol"},{"key":"34_CR63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","volume":"112","author":"D Cota","year":"2003","unstructured":"Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423\u2013431.","journal-title":"J Clin Invest"},{"key":"34_CR64","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","volume":"284","author":"TC Ravinet","year":"2003","unstructured":"Ravinet TC, Arnone M, Delgorge C, et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"34_CR65","unstructured":"Dale LC, Anthenelli RM: Rimonabant as an aid to smoking cessation in smokers motivated to quit: results from a U.S. multicenter study - STRATUS US Trial. Paper presented at the Annual Meeting of the American College of Cardiology, New Orleans, LA, 2004."}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-005-0034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-005-0034-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-005-0034-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:14:16Z","timestamp":1683864856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-005-0034-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11920-005-0034-3","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}